BR0306016A - N3 alkylated benzimidazole derivatives as mek inhibitors - Google Patents
N3 alkylated benzimidazole derivatives as mek inhibitorsInfo
- Publication number
- BR0306016A BR0306016A BR0306016-0A BR0306016A BR0306016A BR 0306016 A BR0306016 A BR 0306016A BR 0306016 A BR0306016 A BR 0306016A BR 0306016 A BR0306016 A BR 0306016A
- Authority
- BR
- Brazil
- Prior art keywords
- mek inhibitors
- compounds
- benzimidazole derivatives
- alkylated benzimidazole
- mammals
- Prior art date
Links
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 title abstract 3
- 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 241000124008 Mammalia Species 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000003463 hyperproliferative effect Effects 0.000 abstract 2
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- JYZIHLWOWKMNNX-UHFFFAOYSA-N benzimidazole Chemical compound C1=C[CH]C2=NC=NC2=C1 JYZIHLWOWKMNNX-UHFFFAOYSA-N 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
"DERIVADOS DE BENZIMIDAZOL N3 ALQUILADO COMO INIBIDORES DA MEK". A presente invenção refere-se a compostos da fórmula (I) e sais e pró-drogas farmaceuticamente aceitáveis dos mesmos, em que W, t, R^ 1, R^ 2^, R^ 7^, R^ 9^, R^ 10^, R^ 11^ e R^ 12^ são conforme definido na especificação. Tais compostos são inibidores da MEK e são úteis no tratamento de doenças hiperproliferativas, tais como câncer e inflamação, em mamíferos. Também é divulgado um método de uso de tais compostos no tratamento de doenças hiperproliferativas em mamíferos e composições farmacêuticas contendo tais compostos."BENZIMIDAZOLE N3 DERIVATIVES ALKED AS MEK INHIBITORS". The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts and prodrugs thereof, wherein W, t, R 1, R 2, R 7, R 9, R 2 ^ 10 ^, R ^ 11 ^ and R ^ 12 ^ are as defined in the specification. Such compounds are MEK inhibitors and are useful in treating hyperproliferative diseases, such as cancer and inflammation, in mammals. Also disclosed is a method of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38768202A | 2002-03-13 | 2002-03-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0306016A true BR0306016A (en) | 2005-01-04 |
Family
ID=33563623
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0306016-0A BR0306016A (en) | 2002-03-13 | 2003-12-11 | N3 alkylated benzimidazole derivatives as mek inhibitors |
Country Status (1)
| Country | Link |
|---|---|
| BR (1) | BR0306016A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010068738A1 (en) | 2008-12-10 | 2010-06-17 | Dana-Farber Cancer Institute, Inc. | Mek mutations conferring resistance to mek inhibitors |
| WO2011106298A1 (en) | 2010-02-25 | 2011-09-01 | Dana-Farber Cancer Institute, Inc. | Braf mutations conferring resistance to braf inhibitors |
| US8435988B2 (en) | 2010-10-06 | 2013-05-07 | Glaxosmithkline Llc | Benzimidazole derivatives as P13 kinase inhibitors |
| WO2013169858A1 (en) | 2012-05-08 | 2013-11-14 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
-
2003
- 2003-12-11 BR BR0306016-0A patent/BR0306016A/en not_active Application Discontinuation
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010068738A1 (en) | 2008-12-10 | 2010-06-17 | Dana-Farber Cancer Institute, Inc. | Mek mutations conferring resistance to mek inhibitors |
| WO2011106298A1 (en) | 2010-02-25 | 2011-09-01 | Dana-Farber Cancer Institute, Inc. | Braf mutations conferring resistance to braf inhibitors |
| US8435988B2 (en) | 2010-10-06 | 2013-05-07 | Glaxosmithkline Llc | Benzimidazole derivatives as P13 kinase inhibitors |
| US8541411B2 (en) | 2010-10-06 | 2013-09-24 | Glaxosmithkline Llc | Benzimidazole derivatives as PI3 kinase inhibitors |
| US8674090B2 (en) | 2010-10-06 | 2014-03-18 | Glaxosmithkline Llc | Benzimidazole derivatives as PI3 kinase inhibitors |
| US8865912B2 (en) | 2010-10-06 | 2014-10-21 | Glaxosmithkline Llc | Benzimidazole derivatives as PI3 kinase inhibitors |
| US9156797B2 (en) | 2010-10-06 | 2015-10-13 | Glaxosmithkline Llc | Benzimidazole derivatives as PI3 kinase inhibitors |
| US9872860B2 (en) | 2010-10-06 | 2018-01-23 | Glaxosmithkline Llc | Benzimidazole derivatives as PI3 kinase inhibitors |
| US10314845B2 (en) | 2010-10-06 | 2019-06-11 | Glaxosmithkline Llc | Benzimidazole derivatives as PI3 kinase inhibitors |
| US10660898B2 (en) | 2010-10-06 | 2020-05-26 | Glaxosmithkline Llc | Benzimidazole derivatives as PI3 kinase inhibitors |
| WO2013169858A1 (en) | 2012-05-08 | 2013-11-14 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0413152A (en) | n3-alkylated benzimidazole derivatives as mek inhibitors | |
| BR122018007328B8 (en) | compound, pharmaceutical composition and use of said compound | |
| BRPI0416692A (en) | heterocyclic mek inhibitors and methods of using these | |
| BRPI0414111A (en) | heterocyclic mek inhibitors and methods of using them | |
| BR0212344A (en) | Compound, process for preparing a compound, use of a compound, method for producing an ileal bile acid inhibitory effect on a warm-blooded animal and pharmaceutical composition | |
| WO2003077855A3 (en) | N3 alkylated benzimidazole derivatives as mek inhibitors | |
| BR0312957A (en) | A compound or a pharmaceutically acceptable salt thereof, use thereof, pharmaceutical composition, and method for producing an inhibitory effect of 11betahsd1 on a warm-blooded animal such as man in need of such treatment. | |
| BR0313942A (en) | Benzimidazole derivatives useful as antiproliferative agents | |
| BRPI0411863A (en) | pyrazolyl indole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | |
| EA200700902A1 (en) | 3-ARYLAMINOPYRIDINE DERIVATIVES | |
| NO20040924L (en) | Benzothiazepine derivatives. | |
| BR0015911A (en) | Benzoimidazole derivatives useful as antiproliferative agents | |
| BR0313041A (en) | Compounds; pharmaceutical compositions; method for the treatment and / or prophylaxis of diseases that are associated with cb1 receptor modulation; and use of compounds | |
| IS6852A (en) | compounds | |
| BR0313160A (en) | Compound, pharmaceutical composition, methods for treating a condition and a susceptible neoplasm in an animal in an animal, process for preparing a compound and use of a compound. | |
| BR0311628A (en) | Compound, process for preparing and use thereof, method for producing an inhibitory effect of ibat on a warm-blooded animal, and, pharmaceutical composition | |
| BR0309493A (en) | Compound, process for preparing a compound, use of a compound, method for producing an ibat inhibitory effect on a warm-blooded animal, and, pharmaceutical composition | |
| BR0315580A (en) | Methylene Urea Derivatives | |
| BR0308212A (en) | Compound, pharmaceutical composition, and use of a compound | |
| BR0309342A (en) | Compound, pharmaceutical composition, use of a compound, and method of treating or prophylaxis of human diseases or conditions. | |
| BRPI0412130A (en) | tetracyclic compounds as c-met inhibitors | |
| BRPI0512252A (en) | compound or a pharmaceutically acceptable salt thereof, pharmaceutical formulation, use of a compound, method of treating a disease, combined product, and process for preparing a compound | |
| PT1109560E (en) | USEFUL COMPOUNDS AS AICARFT INIDERS | |
| BR0306016A (en) | N3 alkylated benzimidazole derivatives as mek inhibitors | |
| BR0008368A (en) | Phenylalaninol derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11Y | Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired |